Market Cap$39.64B
P/E46.64x
PEG Ratio3.31
Div yield—
Beta1.43
ILMN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)91.55%
Price vs S&P 500 (4W)11.26%
PEG Ratio3.31
VGM Score49.46
P/E Ratio (Annual)46.64x
ILMN Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $1.23 | $1.31 | +6.82%(+$0.08) | |
| Q1 2026 | $1.05 | $1.15 | +9.03%(+$0.10) | |
| Q4 2025 | $1.23 | $1.35 | +9.69%(+$0.12) | |
| Q3 2025 | $1.17 | $1.34 | +14.74%(+$0.17) | |
| Q2 2025 | $1.01 | $1.19 | +17.66%(+$0.18) |
ILMN Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.75
3.71
3.71
3.68
Industry Peers — Lab Analytical Instruments(25)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
ILMNIllumina Inc | D | D | A | 8.8x | 6.0% | 66.4% | 19.5% | $262.54 |
| AAgilent Technologies Inc. | D | C | A | 6.6x | 5.4% | 53.9% | 22.2% | $172.97 |
| WATWaters Corp | F | C | A | 9.4x | 6.0% | 50.9% | 7.1% | $436.95 |
| MTDMettler-Toledo International | D | C | A | 7.9x | 5.5% | 60.3% | 26.6% | $1622.29 |
| RVTYRevvity, Inc. | D | D | A | 5.8x | -5.5% | 55.0% | 12.3% | $152.64 |
| AVTRAvantor, Inc. | C | F | A | 1.7x | 0.5% | 31.8% | -4.7% | $16.42 |
| BIO.BBio-Rad Laboratories, Inc. Class B | C | D | B | 3.7x | 0.3% | 51.9% | 1.8% | $364.15 |
| BIOBio-Rad Laboratories, Inc.Class A | C | D | B | 3.7x | 0.3% | 51.9% | 1.8% | $353.70 |
| TXG10x Genomics, Inc. Class A Common Stock | F | D | A | 14.8x | 16.6% | 69.6% | -14.3% | $69.86 |
| BRKRBruker Corporation | D | D | B | 2.4x | 11.6% | 47.7% | -1.5% | $54.80 |
| ALMRAlamar Biosciences, Inc. Common Stock | — | A | B | — | — | — | — | $25.28 |
About Illumina Inc
Illumina is a leading provider of genetic analysis tools and services for life science and clinical applications. The company derives over 90% of revenue from sequencing instruments, consumables, and related services, offering both high-throughput whole genome sequencing and targeted solutions for viral and cancer detection. Illumina also operates a microarray business (9% of 2024 revenue) serving consumer genomics and agricultural markets with more cost-effective genetic screening options.